ADC	Site	Cell Line		
		arpas	540	SKBR3
		IC50	IC50	IC50
		(nM)	(nM)	(nM)
glycosylated Brentuximab DBCO-MMAF 2	C F404	.078	.22	
glycosylated Brentuximab DBCO-MMAF 2	C K121	.040	.12	
glycosylated Brentuximab DBCO-MMAF 2	C N152	.037	.12	
glycoasylated Trastuzumab DBCO-MMAF 2	C F404			.043
ree drug DBCO-MMAF 2		43	46	78

[00457] Cell binding affinities of trastuzumab and brentuximab variants were measured using a FACS-based assay. Briefly, $2x10^5$ Karpas 299 or L540 cells in 25 µl of binding buffer, which consists of PBS containing 0.5% bovine serum albumin (BSA) (Invitrogen; Carlsbad, CA) and 0.09% sodium azide (Sigma; St. Louis, MO) were plated in a 96-well U-bottom polypropylene plate (Greiner Bio-One; Monroe, NC). Antibodies were formulated in binding buffer and 2-fold serial dilutions were prepared in a separate 96-well plate. Equal